Items Tagged with 'Boston Scientific FDA'
BSX Reports Net Sales of $1.828 Billion
On July 26, 2012, Boston Scientific Corporation (NYSE: BSX) released financial results for the second quarter ended on June 30, 2012.
BSX Acquires Cameron Health for $150 Million
On June 8, 2012, Boston Scientific Corporation (NYSE: BSX) closed its acquisition of Cameron Health, Inc. of San Clemente, California, and, as a result, added to its product portfolio the world's first and only commercially available subcutaneous implantable cardioverter defibrillator, called the S-ICD® System.
BSX Receives FDA Approval
On June 4, 2012, Boston Scientific Corporation (NYSE: BSX) announced U.S. Food and Drug Administration (FDA) regulatory approval of 32 mm and 38 mm lengths for the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System.
BSX Recieves FDA Pacemaker Approval
On May 7, 2012, Boston Scientific Corporation (NYSE: BSX) announced U.S. Food and Drug Administration (FDA) approval and market launch of its INGENIO™ and ADVANTIO™ pacemakers and INVIVE™ cardiac resynchronization therapy pacemakers (CRT-P).
On February 22, 2012, Boston Scientific Corporation's (NYSE: BSX) ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System and TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent System have received U.S. Food and Drug Administration (FDA) approval for use in patients experiencing an acute myocardial infarction (AMI), or heart attack.
On December 8, 2011, Boston Scientific Corporation (NYSE: BSX) announced U.S. Food and Drug Administration (FDA) approval of the Infinion™ 16 Percutaneous Lead for its Precision Plus™ Spinal Cord Stimulator (SCS) System, the first rechargeable SCS device for chronic pain management.
On November 30, 2011, Boston Scientific Corporation (NYSE: BSX) announced FDA approval of its INCEPTA™, ENERGEN™ and PUNCTUA™ cardiac resynchronization therapy defibrillators and implantable cardioverter defibrillators to treat heart failure and sudden cardiac death.
Profit from The Turnaround Letter's...
Market-Beating Investment Results
28+ Years of Turnaround Experience
Diverse Stock Picks for Today's Unpredictable Market
Distressed Investing Blog
The S&P 500 is up about 0.6% for the month. That makes the month seem pretty uneventful and benign. But for anyone following the stock market day-by-day, October seemed anything but uneventful and benign. Learn how contrarians can leverage this information for value stock opportunity.
Free Stock Report
Put George Putnam's 28+ years of market-beating, contrarian investing advice to work for you, and give your portfolio a boost with this FREE stock report.
Current Total Returns
Total returns cover the fulll year 2013.
Note: Returns are not adjusted for inflation.
George Putnam has always followed the same straight-forward and highly-profitable investment philosophy. He published his first Turnaround Letter issue back in 1986, and readers have seen extraordinary short and long-term stock profit ever since.
In fact, 11 of this year's 12 sales recommendations saw gains--with five of those enjoying total returns greater than 100%. The Turnaround Letter's average profit for 2014's closed out stock picks is +82%:
2014 Closed Out Purchase Recommendations
* Calculation includes dividends and price changes between purchase recommendation and current price.
Copyright © All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing.